Clearcam Inc.'s Kelling device has an improved view of the market thanks to the closing of a $2.6 million series 2 seed financing round, led by investor and entrepreneur Frank Barbella, CEO of Solv Risk Solutions.
Cryoablation technology firm Icecure Medical Ltd. raised $6 million (₪20.7 million) in an oversubscribed equity offering. The Caesarea, Israel-based company (TASE:ICCM) plans to use the funds for continued expansion of operations in the U.S., Europe and Asia.
Sight Diagnostics Ltd. raised $71 million in series D financing to expand its commercial operations and increase research and development efforts into disease detection from its fingerprick blood analyzer Sight OLO.
Saykara Inc.’s artificial intelligence (AI) assistant enabled the Midwest Institute for Minimally Invasive Therapies (MIMIT Health) to boost practice productivity five-fold. The voice-enabled iOS-based app, named Kara, drafts visit summaries, updates the electronic health record, produces prescriptions, and more with limited involvement from clinicians.
The U.S. FDA expanded the indications for Stryker Corp.’s Neuroform Atlas stent system to include use in the posterior circulation or back of the brain, making the device the only adjunctive stent approved for aneurysms in this challenging location. The Kalamazoo, Mich.-based company’s intracranial coil-assist stent gained its initial indication for the more common aneurysms in the anterior circulation of the neurovasculature in May 2019.
CAPS Medical, of Netanya, Israel, closed a $3.5 million series A round led by Chasing Value Asset Management and the Los Angeles-based Israel Investment Fund Group. The new funds will be used to enable CAPS to undertake its first clinical trial for its minimally invasive, nonthermal plasma device for cancer treatment and further develop its portfolio for the treatment of solid tumors.
More than 70% of individuals using Big Health’s newest digital therapeutic, Daylight, achieved remission of generalized anxiety disorder (GAD) within 10 weeks, and the benefit persisted for at least six months, according to results published in Depression and Anxiety.
Thermo Fisher Scientific expanded its Globalaccess Sequencing Program to include oncology laboratories in addition to research labs working on COVID-19 studies. The company will subsidize a limited number of Genexus systems to help pathology laboratories around the world.
Royal Philips NV reported a 6% decline in year-to-year sales for the second quarter of 2020. While delays in elective procedures suppressed sales in the Amsterdam-based company’s diagnostics and treatment division, the virus boosted demand for connected care and minimized the impact of the coronavirus for the company compared to many competitors.
The Xpert MTB/XDR test developed by the Foundation for Innovative New Diagnostics (FIND) and Cepheid Inc. quickly indicates whether a patient has a dangerous – and rapidly increasing – strain of multidrug resistant tuberculosis (TB). The new test enables clinicians to return results in 90 minutes and see immediately whether the pathogen would respond to standard first- or second-line therapies.
